Eli Lilly touts skyrocketing Mounjaro prescriptions even as it reports an overall slump in 2022 revenue
Eli Lilly is betting big on its type 2 diabetes drug Mounjaro amid skyrocketing prescriptions since its launch.
The company expects US net prices to continue to increase as access is broadened and paid prescriptions for the drug also increase.
Prescriptions for Mounjaro peaked at about 180,000 per week in December, far outpacing its own established type 2 drug Trulicity, according to Lilly data reported in its earnings report on Thursday. While Mounjaro only brought in Q4 revenue of $279.2 million, it’s expected to quickly become a blockbuster.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.